JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Acquired Macular Pigmentation of Unknown Etiology.

Acquired macular pigmentation of unknown etiology is a new umbrella term that encompasses a group of diseases that, while having similar clinical and histological features, their true entities are controversial, and a global consensus regarding these conditions is still lacking. The conditions comprised by the term are ashy dermatosis, erythema dyschromicum perstans, lichen planus pigmentosus, and idiopathic eruptive macular pigmentation. In this review, we compare the clinical and histological features of these conditions that comprise aquired macular pimgentation of unknown etiology, as well as review their responses to treatment.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app